BioMarin Pharmaceutical (BMRN) Competitors $58.14 +0.29 (+0.50%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$57.04 -1.10 (-1.89%) As of 08/1/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BMRN vs. ALNY, BIIB, UTHR, NBIX, INCY, EXEL, EXAS, MDGL, HALO, and IONSShould you be buying BioMarin Pharmaceutical stock or one of its competitors? The main competitors of BioMarin Pharmaceutical include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), Exelixis (EXEL), Exact Sciences (EXAS), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry. BioMarin Pharmaceutical vs. Its Competitors Alnylam Pharmaceuticals Biogen United Therapeutics Neurocrine Biosciences Incyte Exelixis Exact Sciences Madrigal Pharmaceuticals Halozyme Therapeutics Ionis Pharmaceuticals BioMarin Pharmaceutical (NASDAQ:BMRN) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk. Do analysts recommend BMRN or ALNY? BioMarin Pharmaceutical currently has a consensus target price of $93.74, indicating a potential upside of 61.23%. Alnylam Pharmaceuticals has a consensus target price of $392.13, indicating a potential downside of 2.41%. Given BioMarin Pharmaceutical's higher probable upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioMarin Pharmaceutical 0 Sell rating(s) 6 Hold rating(s) 18 Buy rating(s) 0 Strong Buy rating(s) 2.75Alnylam Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 22 Buy rating(s) 0 Strong Buy rating(s) 2.81 Which has more volatility and risk, BMRN or ALNY? BioMarin Pharmaceutical has a beta of 0.18, meaning that its share price is 82% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Is BMRN or ALNY more profitable? BioMarin Pharmaceutical has a net margin of 17.76% compared to Alnylam Pharmaceuticals' net margin of -12.96%. BioMarin Pharmaceutical's return on equity of 11.34% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets BioMarin Pharmaceutical17.76% 11.34% 8.95% Alnylam Pharmaceuticals -12.96%-444.38%-7.54% Which has higher valuation and earnings, BMRN or ALNY? BioMarin Pharmaceutical has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioMarin Pharmaceutical$2.85B3.91$426.86M$2.6921.61Alnylam Pharmaceuticals$2.25B23.30-$278.16M-$2.09-192.25 Does the media prefer BMRN or ALNY? In the previous week, Alnylam Pharmaceuticals had 26 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 43 mentions for Alnylam Pharmaceuticals and 17 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 1.08 beat Alnylam Pharmaceuticals' score of 0.85 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 9 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 14 Very Positive mention(s) 3 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of BMRN or ALNY? 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 0.9% of BioMarin Pharmaceutical shares are held by company insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryBioMarin Pharmaceutical beats Alnylam Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get BioMarin Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMRN vs. The Competition Export to ExcelMetricBioMarin PharmaceuticalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.09B$3.00B$5.47B$9.52BDividend YieldN/A2.43%4.73%4.08%P/E Ratio21.6117.6228.6723.80Price / Sales3.91270.73400.1878.09Price / Cash17.8241.9535.4557.96Price / Book1.968.508.275.55Net Income$426.86M-$55.06M$3.24B$259.03M7 Day Performance-1.47%-3.98%-3.69%-4.59%1 Month Performance1.70%9.59%4.33%4.46%1 Year Performance-30.95%6.72%25.95%18.03% BioMarin Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMRNBioMarin Pharmaceutical4.9771 of 5 stars$58.14+0.5%$93.74+61.2%-31.3%$11.09B$2.85B21.613,040News CoverageUpcoming EarningsHigh Trading VolumeALNYAlnylam Pharmaceuticals3.8859 of 5 stars$320.520.0%$347.75+8.5%+49.6%$41.79B$2.25B-153.362,230Trending NewsAnalyst ForecastBIIBBiogen4.8487 of 5 stars$122.68-1.8%$186.37+51.9%-37.4%$18.31B$9.82B12.117,605Trending NewsEarnings ReportAnalyst ForecastUTHRUnited Therapeutics4.9608 of 5 stars$293.12+0.4%$383.08+30.7%-10.2%$13.22B$2.88B11.701,305Trending NewsEarnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionGap UpNBIXNeurocrine Biosciences4.687 of 5 stars$131.83-0.1%$163.87+24.3%-15.8%$13.05B$2.36B44.691,800Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionINCYIncyte4.7569 of 5 stars$67.38-0.7%$74.47+10.5%+17.3%$13.04B$4.24B210.572,617Trending NewsAnalyst ForecastEXELExelixis4.9371 of 5 stars$44.26-0.5%$45.28+2.3%+53.8%$12.07B$2.17B20.121,147Trending NewsEarnings ReportAnalyst ForecastOptions VolumeAnalyst RevisionEXASExact Sciences4.4246 of 5 stars$48.36-4.2%$70.50+45.8%-17.5%$9.12B$2.76B-8.787,000Positive NewsUpcoming EarningsMDGLMadrigal Pharmaceuticals4.2722 of 5 stars$330.94-1.0%$420.63+27.1%+8.5%$7.35B$180.13M-18.3390Upcoming EarningsHALOHalozyme Therapeutics4.7755 of 5 stars$55.92-0.9%$62.70+12.1%+7.2%$6.96B$1.08B14.87390News CoveragePositive NewsUpcoming EarningsIONSIonis Pharmaceuticals4.5496 of 5 stars$41.55-0.5%$57.13+37.5%-16.2%$6.61B$717.25M-13.901,069Trending NewsEarnings ReportAnalyst ForecastInsider Trade Related Companies and Tools Related Companies ALNY Competitors BIIB Competitors UTHR Competitors NBIX Competitors INCY Competitors EXEL Competitors EXAS Competitors MDGL Competitors HALO Competitors IONS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMRN) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BMRN Stock Alerts